Accelerating the Discovery and Development of Novel Cancer and
Infectious Disease Therapeutics
DOYLESTOWN, Pa.--(BUSINESS WIRE)--
PMV Pharmaceuticals, Inc., announced the appointment of renowned
biotechnology business leader, Steven Holtzman to the board of
directors. Mr. Holtzman’s appointment brings the total board to five
members as he joins current members Arnold Levine, Ph.D., David Mack,
Ph.D., Arnold Oronsky, Ph.D. and Douglas Fisher, M.D.
“The addition of Steve Holtzman to our Board provides us with important
strategic insights as we look to develop our cancer and infectious
disease therapeutics. Steve’s proven business and commercial expertise
will be of great value as our product portfolio continues to mature,”
David Mack, Ph.D., President and CEO of PMV Pharmaceuticals said.
PMV Pharma is pioneering the discovery and development of p53 targeted
small molecule drugs for the treatment of cancer and infectious disease.
Founded by p53 thought leader Dr. Arnold Levine and world-renowned
virologist Dr. Thomas Shenk, in collaboration with co-founder Dr. David
Mack, PMV Pharma possesses unique insights into p53 biology and the
discovery of selective modulators of p53 and its pathway.
p53’s importance in human biology is profound: it is the most commonly
mutated protein in human cancers with more than half of all tumors
containing mutant p53. It is also a key cellular defense against viral
infection and is known to suppress the replication of numerous viruses.
“PMV Pharmaceuticals has assembled a world-class team. Now is the time
to apply the knowledge accumulated over decades of p53 research into the
discovery and development of life changing medicines. The era of big
biology is upon us, and I expect PMV Pharma to be a major player in a
new generation of medicines,” Steve Holtzman said.
Steve Holtzmancurrently serves as Executive Vice President,
Corporate Development for Biogen Idec where he is responsible for
Business Development and M&A, and Program Leadership & Management of the
company’s late-stage product candidates and marketed products. Prior to
joining Biogen Idec, Mr. Holtzman served as the Founder, CEO and Chair
of the Board of Directors of Infinity Pharmaceuticals, Inc., a cancer
drug discovery and development company. Mr. Holtzman was an early leader
and Chief Business Officer of Millennium Pharmaceuticals, Inc., now a
subsidiary of Takeda Pharmaceuticals. Prior to joining Millennium, he
was a Founder, a member of the Board, and the Executive Vice President
of DNX Corporation, the first commercial enterprise devoted to the
development of agricultural, biomedical and pharmaceutical applications
of transgenic technology.
Steve received his B.A. in Philosophy (1976) from Michigan State
University and his B.Phil. graduate degree in Philosophy (1979) from
Corpus Christi College, Oxford University, which he attended as a Rhodes
About PMV Pharma
PMV Pharma is developing first-in-class p53 and p53 pathway modulators
for the treatment of cancer and infectious disease. Bringing together
leaders in the field to utilize over three decades of p53 biology, PMV
Pharma combines unique biological understanding with pharmaceutical
development focus. PMV Pharma received initial funding from premier
venture capital firm InterWest Partners and has corporate operations in
Redwood City, California and Research and Development in Doylestown,
For additional information about PMV Pharma, its scientific platform,
management team, board of directors and scientific advisory board,
please visit: PMVpharma.com
PMV Pharma, Inc.
David Mack, Ph.D., 650-241-2822
Source: PMV Pharmaceuticals, Inc.